News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
13
2026
-
05
Dual Exhibitions, Full-Chain Collaboration | Keyuan Pharmaceutical, together with its subsidiary Linuo Pharmaceutical, proudly showcases its offerings at the Shanghai International Pharmaceutical Dual Exhibitions!
Classification：
Corporate News
On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediates, Packaging & Equipment Exhibition (API China) opened simultaneously at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing integrated API–formulation synergy, end-to-end product demonstrations, and brand‑wide resonance. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore emerging industry trends, expand new avenues for collaboration, and co‑create a thriving new ecosystem for the pharmaceutical and healthcare sectors.
Shanghai Unites Strengths, Moving Forward Together
The dual exhibitions illuminate a new chapter, fostering collaboration for mutual benefit.
This year’s dual exhibitions are being held jointly, with a combined exhibition space exceeding 170,000 square meters. They bring together nearly 4,000 high-quality exhibitors and 200,000 professional visitors, spanning the entire pharmaceutical value chain—from active pharmaceutical ingredients and finished dosage forms to packaging materials, equipment, and distribution. As China’s largest, most prestigious, and most influential annual flagship event in the pharmaceutical industry, it provides an authoritative and highly efficient platform for companies to engage in technological exchange, showcase their brands, and facilitate business matchmaking.
At the exhibition booth, Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President, led the company’s core team to the front lines, engaging in in-depth exchanges and precision negotiations with new and longstanding partners from across the country. They carefully listened to market needs, analyzed industry trends, and jointly discussed strategies for channel expansion and industrial collaboration, fully demonstrating the company’s customer-centric, market-oriented development philosophy and its unwavering commitment to deepening its presence in the pharmaceutical sector.
Parent Company Leads the Way, Building a Solid Foundation with Robust Capabilities
Integrated planning strengthens the foundation, while digital and intelligent technologies empower quality and efficiency.
Keyuan Pharmaceutical, anchored by an integrated API–formulation strategy, focuses on its core therapeutic areas—diabetes, anesthesia, cardiovascular health, and psychiatry—and showcases high‑quality chemical APIs, specialty intermediates, and cutting‑edge green intelligent manufacturing solutions at the API China exhibition. Leveraging AI‑driven, all‑scenario applications, data management, and smart manufacturing as strategic pillars, the company is comprehensively advancing the digital and intelligent transformation of its production facilities. It has established dual R&D centers in Beijing and Jinan, supported by six robust technology platforms, and continues to drive breakthroughs in key technologies such as enzyme catalysis, continuous flow processes, and chiral catalysis. With a commitment to reliable supply, stringent quality control, and world‑class production capabilities, Keyuan has garnered significant attention from global buyers and strategic partners.
In the first quarter of 2026, the company reported operating revenue of RMB 161 million, up 45.05% year over year, and net profit attributable to shareholders of RMB 30.07 million, an increase of 30.27% year over year. Both operating performance and earnings quality improved in tandem, laying a solid foundation for the Group’s high-quality development.
Subsidiary Revitalized, New Products Shine
A full‑chain matrix illuminates the City of Shanghai, while匠心‑crafted new products usher in a new journey.
Linuo Pharmaceutical made a high‑profile appearance at the national pharmaceutical trade fair, leveraging its full‑chain synergy with Keyuan Pharmaceutical and harnessing capital to build a comprehensive product portfolio spanning all dosage forms—including injectables, oral solutions, drops, liniments, pastes, and sprays. Guided by pressing market needs, the company showcased premium formulations across diverse therapeutic areas such as chronic disease management, anti‑infection, and anti‑inflammatory treatments.
On the eve of the conference, at the client appreciation gala, Linuo Pharmaceutical solemnly held a launch ceremony for six major new products, officially unveiling them. Alendronate sodium tablets, levocetirizine dihydrochloride tablets, vancomycin hydrochloride for injection, isavuconazole sulfate for injection, betahistine hydrochloride tablets, and diphenhydramine hydrochloride tablets—this report provides a comprehensive analysis of their clinical value, market prospects, and distribution policies.
Raw Material–Formulation Synergy: Steady Progress for Long-Term Success
Dual-core synergy builds end-to-end competitiveness, demonstrating resilient growth across market cycles.
In recent years, Keyuan Pharmaceutical and Linuo Pharmaceutical have adhered to an integrated parent–subsidiary model driven by dual core capabilities and coordinated development across the entire value chain. Guided by five foundational strategies—AI‑powered all‑scenario applications, technological innovation, internet‑based thinking, data management, and investment & financing—they have established world‑class smart manufacturing facilities for APIs, injectables, solid dosage forms, and other product lines. This has enabled deep, end‑to‑end integration between API and formulation production, as well as between excipients and finished products, ensuring rigorous quality control at the source, reducing costs while boosting efficiency, and securing supply chains. As a result, they have built robust, full‑chain core competencies spanning R&D innovation, lean manufacturing, and market promotion, sustaining steady growth and demonstrating strong resilience in navigating industry cycles.
The brand sets sail, with a promising future.
Dual Exhibitions Empower and Showcase Excellence, Joining Forces to Build a Healthy Future
The dual exhibitions, held under one roof, underscore the strength of our brand; seamless collaboration across the entire value chain ushers in a new chapter of growth. This joint appearance at the Shanghai International Pharmaceutical Exhibition is not only a comprehensive showcase of Koyuan Pharmaceutical Group’s achievements in building an end-to-end industrial ecosystem, pursuing integrated development, and implementing brand‑driven operations, but also a significant step in the Group’s strategic commitment to deepening its presence in the domestic market while embracing global opportunities, thereby actively contributing to the broader drive for high‑quality development in the pharmaceutical industry.
Looking ahead, Keyuan Pharmaceutical will continue to join forces with Lino Pharmaceutical, staying true to its original mission of caring for life and health and safeguarding a better future. Guided by innovation as its soul, intelligent manufacturing as its foundation, and collaboration as its wings, the company will steadily strengthen R&D investment, upgrade smart manufacturing, optimize its product portfolio, and deepen its global footprint. Working hand in hand with partners at home and abroad, Keyuan Pharmaceutical will contribute even greater efforts to advancing China’s pharmaceutical industry toward high-end, intelligent, and international standards, and to supporting the Healthy China initiative and the national strategy of building a strong brand nation.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China